# Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

> **NCT01541332** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Oncotherapeutics** · enrollment: 70 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Pegylated Liposomal Doxorubicin (PLD)
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01541332
- **Lead sponsor:** Oncotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-02
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2016-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01541332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01541332, "Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01541332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*